Discretionary Denials at Patent Court Thwart Generic Drugmakers

February 19, 2026

NBA CLS 39th Annual Corporate Counsel Conference

Axinn is pleased to sponsor the National Bar Association Commercial Law Section’s 39th Annual Corporate Counsel Conference, being held February 18-21 in Dana Point, California.

Sponsorship

Antitrust

February 5, 2026

New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review

On February 5, Axinn antitrust practice chair Mike Keeley will speak on the "Regulated Markets, Competition and Competitiveness" panel at Concurrences' New Frontiers of Antitrust Conference in Paris.

Speaking Engagement

Antitrust

January 29, 2026

GCR Live Global: Navigating the Future of Antitrust 2026

On January 29, Axinn partner Jacklin Chou Lem will speak on the "Antitrust: Novel Theories of Harm – Where are the Limits?" panel at Global Competition Review's Navigating the Future of Antitrust Conference, being held January 28-30 in Miami.

Speaking Engagement

Antitrust

December 4, 2025

Stakeholders 25th Annual CYOC Career Development Conference

Axinn is pleased to sponsor the Stakeholders Charting Your Own Course (CYOC) Career Development Conference, being held December 4-7 in Orlando.

Sponsorship

Antitrust

November 20, 2025

American Investment Council’s General Counsel Day

On November 20, Partner John Harkrider will speak on the M&A and Antitrust panel at the American Investment Council’s General Counsel Day, taking place at Debevoise & Plimpton LLP in New York.

Speaking Engagement

Antitrust

November 19, 2025

Informa 34th Annual Advanced EU Brussels Conference

On November 19, Axinn partner Jimmy Attridge will speak on the "Competition Policy in the New Geopolitical Landscape" panel at Informa's Advanced EU Brussels Conference, being held November 18-19.

Speaking Engagement

Antitrust

November 19, 2025

Kisaco Research Pharma and Biotech Patent Litigation Summit 2025

On November 19, Axinn partner Matthew Murphy will speak on the "Understanding IP Exclusivity Rights Considering the Latest Antitrust Landscape" panel at Kisaco Research's Pharma & Biotech Patent Litigation Summit, being held November 18-19 in Philadelphia.

Speaking Engagement

Intellectual Property

November 18, 2025

GCR Live: Women in Antitrust 2025

On November 18, Axinn partner Lisl Dunlop will speak on "The Next Four Years: Merger Control Following U.S. Leadership Changes" at Global Competition Review's Women in Antitrust conference in Washington, DC.

Speaking Engagement

Antitrust

November 18, 2025

Global Legal Group Global Class Actions Symposium 2025

On November 18, Axinn partner Craig Reiser will chair the "Class Actions in the USA" panel at Global Legal Group's Global Class Actions Symposium, being held November 18-19 in London.

Speaking Engagement

Litigation & Trials

November 12, 2025

Biosimilar Approval Pathway Changes Sponsors Need to Monitor

Axinn partner Matthew Murphy was quoted in the Lexology Pro article, "Biosimilar Approval Pathway Changes Sponsors Need to Monitor."

Media Mentions

Intellectual Property

November 12, 2025

ITCTLA Mock Hearing Program 2025

Axinn partners Brian Johnson and Joseph Micallef have been selected to participate as coaches for the International Trade Commission Trial Lawyers Association’s Mock Hearing Program in Washington, DC on November 12. Associates Raymond Braha and Cassie Goodnight have been selected to participate as NEXT Advocates.

Speaking Engagement

Intellectual Property

November 11, 2025

United States: Enforcement Agencies Display Openness to Negotiating and Accepting Remedies Amid HSR Growing Pains

Axinn partners Lisl Dunlop, Bradley Justus, and James Hunsberger, along with associate Aigerim Saudabayeva, authored the global introduction and the U.S. chapter titled, “United States: Enforcement Agencies Display Openness to Negotiating and Accepting Remedies Amid HSR Growing Pains” for Global Competition Review's Market Review: Merger Control 2025.As part of a comprehensive review of the past year in U.S. merger control, the chapter examines how, even as the new HSR rules introduce challenges, the DOJ and FTC have shown greater openness to negotiating and accepting remedies—creating a more predictable, business-friendly environment for dealmaking. It also highlights key enforcement trends, the growing role of state-level review, and practical advice to get deals cleared quickly.

Antitrust

Discretionary Denials at Patent Court Thwart Generic Drugmakers

Related People

Related Services

Featured Insights

Featured Insights